Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04265534
Title	KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE)
Acronym	KEAPSAKE
Recruitment	Terminated
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Calithera Biosciences, Inc
Indications	lung non-squamous non-small cell carcinoma
Therapies	Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium + Telaglenastat Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium
Age Groups:	senior \| adult
Covered Countries	USA